The protumorigenic potential of FTY720 by promoting extramedullary hematopoiesis and MDSC accumulation
Authors:
- 20 February 2017
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 36 (26) , 3760-3771
Abstract
FTY720 (also called fingolimod) is recognized as an immunosuppressant and has been approved by the Food and Drug Administration to treat refractory multiple sclerosis. However, long-term administration of FTY720 potentially increases the risk for cancer in recipients. The underlying mechanisms remain poorly understood. Herein, we provided evidence that FTY720 administration potentiated tumor growth. Mechanistically, FTY720 enhanced extramedullary hematopoiesis and massive accumulation of myeloid-derived suppressor cells (MDSCs), which actively suppressed antitumor immune responses. Granulocyte–macrophage colony-stimulating factor (GM-CSF), mainly produced by MDSCs, was identified as a key factor to mediate these effects of FTY720 in tumor microenvironment. Furthermore, we showed that FTY720 triggers MDSCs to release GM-CSF via S1P receptor 3 (S1pr3) through Rho kinase and extracellular signal-regulated kinase-dependent pathway. Thus, our findings provide mechanistic explanation for the protumorigenic potentials of FTY720 and suggest that targeting S1pr3 simultaneously may be beneficial for the patients receiving FTY720 treatment.Keywords
This publication has 50 references indexed in Scilit:
- Dysregulated Hematopoietic Stem and Progenitor Cell Activity Promotes Interleukin-23-Driven Chronic Intestinal InflammationImmunity, 2012
- Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A‐RIPK1‐dependent necroptosisEMBO Molecular Medicine, 2012
- Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic CancerCancer Cell, 2012
- Origins of tumor-associated macrophages and neutrophilsProceedings of the National Academy of Sciences, 2012
- Myeloid derived suppressor cells in human diseasesInternational Immunopharmacology, 2011
- Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and functionTrends in Immunology, 2011
- IL‐1β regulates a novel myeloid‐derived suppressor cell subset that impairs NK cell development and functionEuropean Journal of Immunology, 2010
- STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumorsNature Medicine, 2010
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- S1P1 Receptor Signaling Overrides Retention Mediated by Gαi-Coupled Receptors to Promote T Cell EgressImmunity, 2008